VICTORIA, BC, Oct. 05, 2020 /CNW/ - IMMUNOPRECISE
ANTIBODIES LTD. (the "Company" or "IPA") (TSXV: IPA) (OTCQB: IPATF)
(FSE: TQB2), a leader in full-service, therapeutic antibody
discovery and development, today announced that Dr. Jennifer Bath, CEO of IPA, was invited Sunday
morning, October 4th, as a
guest on Fox & Friends with Anchor Jedediah Bila at
7:15a.m. ET.
Dr. Bath explained the unique functions of cocktail therapies as
they pertain to SARS-CoV-2, including the antibody treatment
administered to President Trump. She also expanded on
the importance of the initial design for such strategies and how
early steps can be taken to support the safety and efficacy of
treatments, but that these tests take time.
IPA launched their Polytope™ Therapy Cocktail, which they
believe to be the most promising approach to address a virus like
SARS-CoV-2, as it also aims to protect and treat both current and
future strains and variants of SARS.
To view Dr. Bath's interview on Fox & Friends please
click here.
About ImmunoPrecise Antibodies Ltd.
ImmunoPrecise is
a global technology platform company with end-to-end solutions
empowering companies to discover and develop therapies against any
disease. The Company's experience and cutting-edge technologies
enable unparalleled support of its partners in their quest to bring
innovative treatments to the clinic. ImmunoPrecise's full-service
capabilities dramatically reduce the time required for, and the
inherent risk associated with, conventional multi-vendor product
development. For further information,
visit www.immunoprecise.com or contact
solutions@immunoprecise.com.
Forward Looking Information
This news release contains statements that, to the extent they
are not recitations of historical fact, may constitute
"forward-looking statements" within the meaning of applicable
Canadian securities laws. The Company uses words such as "may",
"would", "could", "will", "likely", "expect", "believe", "intend",
"should" and similar expressions to identify forward-looking
statements and include the Company's beliefs with respect to the
potential for its antibodies to be further developed or approved to
treat COVID-19 (or SARS-CoV-2) or to complete any transactions
with respect to those antibodies. Any such forward-looking
statements are based on assumptions and analyses made by
ImmunoPrecise in light of its experience and its perception of
historical trends, current conditions and expected future
developments. However, whether actual results and developments will
conform to ImmunoPrecise's expectations and predictions is subject
to any number of risks, assumptions and uncertainties. Many factors
could cause ImmunoPrecise's actual results to differ materially
from those expressed or implied by the forward-looking statements
contained in this news release. Such factors include, among other
things, actual revenues and earnings for IPA being lower than
anticipated, and those risks and uncertainties described in
ImmunoPrecise's annual management discussion and analysis for the
previous quarter ended April 30, 2020
which can be accessed at www.sedar.com. The
"forward-looking statements" contained herein speak only as of the
date of this press release and, unless required by applicable law,
ImmunoPrecise undertakes no obligation to publicly update or revise
such information, whether as a result of new information, future
events or otherwise.
Neither the TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
SOURCE ImmunoPrecise Antibodies Ltd.